Insider buying last 90 days
No open-market insider purchases were filed for BIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Bio-Rad's week centers on its Q3 2026 results, reported 4 November. Revenue came in at roughly $656 million, up 0.5% reported and 0.7% currency-neutral, marking the company's first currency-neutral growth quarter of 2026. Clinical Diagnostics rose 2.7% and returned to growth, Life Science dipped 2.8% overall but grew 2.5% excluding Process Chromatography, and ddPCR instrument revenue grew more than 20% for a third straight quarter. Non-GAAP gross margin expanded to 54.5%, EPS of $2.65 topped the $2.23 estimate, and full-year sales guidance was affirmed at $2.51 billion to $2.60 billion. The stock's reaction to the print was muted, down 1.6%.
Shares closed at $388.31, up 1.8%, and sit above both the 50-day average of $373.63 and the 200-day average of $315.40, with the shorter average above the longer one. The GekkoIndex reads 50.9, placing it in the Neutral zone, though the index has slipped 6.6 points over five days. Price sits 8.4% above Gekko Fair Value of $358.17.
The next earnings date falls on 11 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective windows, and a single tracked analyst holds a buy rating with a $335 consensus target, implying downside of 13.7% from current levels. Seasonality from this point has averaged -0.3% over the next 20 trading days across five years, rising in four of them, a mixed historical pattern worth noting alongside the current stretch above both moving averages.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Bio-Rad Laboratories scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Averages disagree
Close $366.36 sits between the 50-day ($372.95) and 200-day ($316.99) averages, or the averages disagree.
See the chart60, Accumulation
Reading 60 is in the Accumulation zone.
See the GekkoIndex0.0% above
Price is within 5% of Gekko Fair Value (0% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 88 days
Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.
See earnings−1.3% on average
From this point in the calendar, the next 20 trading days averaged −1.3% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Bio-Rad Laboratories closed at $366.36 on Nov 13, 2026, +11.9% over the past year, inside a 52-week range of $236.73 to $396.23.
Use the left and right arrow keys to read daily values.
Put BIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Bio-Rad Laboratories makes and sells equipment, reagents, and testing systems used in life science research and clinical diagnostics. Its work includes tools for separating and analyzing chemical and biological materials, and it is known for supplying laboratories with both instruments and the diagnostic kits that go with them. Customers reach the company across the United States, Canada, Europe, Asia, and Latin America.
The business runs through two divisions. The Life Science division builds reagents, instruments, and lab equipment for work in proteomics, genomics, biopharmaceutical manufacturing, cellular biology, and food safety, selling to universities, medical schools, government and industrial research bodies, pharmaceutical and biotech firms, and food producers and testing labs. The Clinical Diagnostics division supplies test systems, diagnostic kits, informatics tools, and quality control products for niche areas of in vitro diagnostics, serving reference and hospital laboratories, newborn screening centers, physicians' offices, and transfusion labs. Products reach customers through a direct sales force alongside distributors, agents, brokers, and resellers.
Bio-Rad Laboratories was founded in 1952 and is based in Hercules, California. Its shares are listed on the NYSE under the ticker BIO.
Bio-Rad Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60, in the Accumulation zone, up 5.6 points over five sessions.
Up 5.6 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −1.0% | −0.6% | ||
| Accumulation (current zone) | 207 | +1.2% | +2.8% | ||
| Neutral | 408 | +0.1% | +0.1% | ||
| Distribution | 44 | −1.2% | +0.2% | ||
| Selling | 2 | Too few readings yet | |||
Average BIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Bio-Rad Laboratories trades level with Gekko Fair Value of $366.44, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Bio-Rad Laboratories shares are worth, recalculated every trading day.
$366.44
Gekko Fair Value, Nov 14, 2026
0.0% from fair value · About fair value
At the end of Aug 2026 the price was 17.5% above the estimate.
No open-market insider purchases were filed for Bio-Rad Laboratories, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BIO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Bio-Rad Laboratories has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds BIO.
Bio-Rad Laboratories reports on Feb 11, 2027, after the close (88 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 11, 2027
Expected after the close, 88 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $2.65 est $2.23 | $656.4M est $649.9M | −1.6% |
| Aug 4, 2026 | $2.62 est $1.75 | $651.0M est $624.0M | +3.9% |
| Apr 30, 2026 | $1.89 est $1.97 | $592.1M est $589.9M | −6.8% |
| Feb 12, 2026 | $2.51 est $2.57 | $693.2M est $688.8M | −12.6% |
| Oct 29, 2025 | $2.26 est $2.30 | $653.0M est $694.6M | −7.8% |
| Jul 31, 2025 | $2.61 est $1.93 | $651.6M est $633.8M | +13.8% |
| May 1, 2025 | $2.54 est $1.73 | $585.4M est $573.2M | −3.2% |
| Feb 13, 2025 | $2.90 est $2.88 | $667.5M est $679.8M | −11.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Bio-Rad Laboratories is $356.67, −2.6% from the last close, from 1 firm rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 1 firm.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 27 | RBC Capital | $390 | +6.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Bio-Rad Laboratories averaged −1.3% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 2 of 5 |
| Next 10 trading days | −2.1% | 1 of 5 |
| Next 15 trading days | −3.4% | 1 of 5 |
| Next 20 trading days | −1.3% | 2 of 5 |
| Next 30 trading days | −1.9% | 1 of 5 |
For scale, BIO’s typical 20-trading-day move in either direction is about 5.6%.
Bio-Rad Laboratories’s market cap is $9.85B, with a P/E ratio of 10.3 and revenue of $2.59B over the last twelve months.
Coverage of Bio-Rad Laboratories this week reads neutral: 1 positive, 3 neutral and 1 negative headlines.
Bio-Rad Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Bio-Rad Laboratories’s market cap is $9.85B at the Nov 13, 2026 close of $366.36, with 21.83M shares outstanding. The shares trade on a P/E ratio of 10.3.
The consensus analyst 12-month price target for Bio-Rad Laboratories is $356.67, −2.6% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Bio-Rad Laboratories is about fair value: the Nov 13, 2026 close of $366.36 is level with Gekko Fair Value of $366.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Bio-Rad Laboratories is expected to report on Feb 11, 2027, after the market closes (88 days away). Analysts expect earnings of $2.83 per share on revenue of $688.7M. Bio-Rad Laboratories beat the earnings estimate in 5 of its last 8 reports, moving 7.6% on average across the report.
Bio-Rad Laboratories’s 52-week high is $396.23 and its 52-week low is $236.73; it closed at $366.36 on Nov 13, 2026, +11.9% over the past year. Over the last five years the shares peaked at $784.39 on Nov 17, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and earnings risk), 2 as mixed (trend and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.